share_log

Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target

Benzinga ·  Nov 13 06:46  · Ratings

Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment